Clinical trials
Acute Lymphoblastic Leukemia clinical trials
Below are recruiting acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 398 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05327894RecruitingPhase 3
Infants with a specific leukemia genetic change
This study tests a treatment plan for babies under 1 year with leukemia that has a KMT2A gene rearrangement. It may help by trying to improve outcomes in this high-risk group, sometimes using a drug called blinatumomab (depending on eligibility).
Buenos AiresAges 1 day–1 year - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT06355583RecruitingPhase 2
Gut bacteria transplant before stem cell transplant
This trial tests whether giving a transplant of healthy gut bacteria (fecal microbiota transplant) before a stem cell transplant can improve outcomes for people with certain blood cancers or bone marrow disorders.
Birmingham, EnglandAges 18 years+ - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06389305Recruiting
CIK cell therapy for B-cell leukemia after CAR-T failure
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Beijing, Beijing MunicipalityAges 1–39 - NCT06392581Recruiting
Fungal infection risk in Ph-Neg acute lymphoblastic leukemia
This study looks at how often patients with a type of leukemia called Philadelphia-negative acute lymphoblastic leukemia (ALL) get serious fungal infections. It will help doctors understand who is at higher risk and how to better protect patients during treatment.
BresciaAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06408194RecruitingPhase 1
CD22 CAR T cells after Kymriah for B-cell cancers
This trial tests a new CAR T-cell therapy that targets CD22, after you've already received or been scheduled for a standard CD19-targeting CAR T-cell therapy (Kymriah). The goal is to see if giving a second type of CAR T cells can help when the first one doesn't work or the cancer returns.
Palo Alto, CaliforniaAges 1–25 - NCT06420076RecruitingPhase 1/Phase 2
Sequential CAR-T therapy for CD5/CD7 positive T-cell leukemia/lymphoma
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Beijing, Beijing MunicipalityAges 2–90 - NCT06427330RecruitingPhase 2
Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
TianjinAges 18 years+ - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT06450067Recruiting
Inaticabtagene Autoleucel for Relapsed or Refractory ALL
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06452732Recruiting
Leukemia stem cell test for AML relapse in children
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT06477549RecruitingPhase 2
Comparing Two Drug Combinations for Stem Cell Transplant
This study compares two different drug combinations (BeFluBu and FluBuRux) used before a stem cell transplant from a half-matched (haploidentical) donor. The goal is to see which combination works better to prepare your body for the transplant and control your blood cancer.
Saint PetersburgAges 18–75 - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06508099RecruitingPhase 2
Vitamin A and D supplements after stem cell transplant
This trial tests whether taking vitamin A and D after a stem cell transplant can help improve recovery. It is for people with certain blood cancers who have a matched donor and are in remission or have low disease activity.
Saint PetersburgAges 18 years+ - NCT06514768RecruitingEarly Phase 1
JY231 injection for B-cell acute lymphoblastic leukemia
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
Kunming, YunnanAges Up to 75 years - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT06575296RecruitingPhase 1
Revumenib after stem cell transplant for acute leukemia
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
Duarte, CaliforniaAges 2 years+ - NCT06580301RecruitingPhase 1/Phase 2
Study of YK012 for relapsed or refractory B-ALL
This trial tests a new drug, YK012, for people with a certain kind of B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not gotten better after standard therapies. It aims to see if the drug is safe and works against these leukemia cells that have the CD19 marker.
Guangzhou, GuangdongAges 18–75 - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06598722RecruitingPhase 2
BCL-2 inhibitor plus HyperCVAD for T-cell lymphoma
This trial tests adding a BCL-2 inhibitor drug to a standard chemotherapy regimen (HyperCVAD) for people newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see if the combination works better than chemotherapy alone.
ShanghaiAges 18–60 - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 398 recruiting acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.